OMAHA, Nebraska (November 4, 2024)— UNeMed released today its 2024 annual report, detailing key metrics, highlights and notable achievements during the fiscal year ending in 2024.
The report focuses on successes that highlight a few of UNeMed’s more recent commercial achievements. Specifically, the report holds up two UNeMed startup companies that cleared FDA in early 2024: Virtual Incision and Carecubes.
Virtual Incision is a surgical robotics company built on a collaboration between a former University of Nebraska Medical Center surgeon and a University of Nebraska-Lincoln engineer.
Carecubes is built around the development of a rapidly deployable biocontainment unit created by UNMC’s world-renown infectious diseases team of clinicians and researchers. The Carecube was initially conceived during an Ebola outbreak in Africa, but later perfected in direct response to the COVD-19 pandemic.
The 2024 annual report also notes three new additions to its board of directors before looking ahead to two promising early-stage startups, Exavir and University Medical Devices.
Exavir is developing a novel therapeutic formulation for HIV medication. If all goes according to plan, Exavir could make it possible for HIV patients to receive one or two annual treatments, rather than the strictly regimented daily dosing that is currently required to successfully manage the disease.
University Medical Devices has several innovations in its pipeline, but the cornerstone device is a nasal sample collection device that renders obsolete the painful swabs that gained notoriety during the pandemic.
Finally, the 2024 annual report presents core metrics for all of UNeMed’s activities, recaps the 2023 Innovation Awards and lists all U.S. patents that UNeMed secured on behalf of University of Nebraska inventors.
The complete annual report can be viewed online (see below), and printed copies are also available. Contact UNeMed to receive a free printed copy.
